Business Wire

New AI-Powered Experian Assistant for Model Risk Management Streamlines and Accelerates Governance Processes

Share

Experian today announced the launch of Experian Assistant for Model Risk Management, a first-of-its-kind solution to help financial institutions govern and manage models more efficiently across the entire model‑development lifecycle. Fully integrated into the Experian Ascend Platform™ and powered by ValidMind technology, this solution helps accelerate model validation, improve auditability and transparency, and may aid financial institutions in reducing regulatory and reputational risk. This launch follows last October’s introduction of the award-winning Experian Assistant and its AI-enabled model-lifecycle features.

“Manual documentation, siloed validations and limited performance model monitoring can increase risk and slow down model deployment,” said Vijay Mehta, EVP, Global Solutions and Analytics, Experian Software Solutions. “Adhering to model-risk-management guidelines can be a tremendous strategic advantage for financial institutions when they can create, review and validate documentation quickly and at scale, and this new solution offers these capabilities.”

As financial institutions accelerate innovation, they must balance the move toward GenAI-enabled capabilities with compliance to global model-risk-management guidelines such as SR 11-7 (US) and SS1/23 (UK). Experian Assistant for Model Risk Management offers financial institutions with customizable, pre-defined templates, centralized model governance repositories, and transparent internal workflow approvals—empowering them to meet regulatory guidelines with confidence and efficiency.

“Our partnership with Experian represents a major step forward in operationalizing AI for governance and model risk management,” said ValidMind CEO Jonas Jacobi. “By embedding ValidMind’s automation and governance capabilities into the Experian Assistant for Model Risk Management, we’re helping financial institutions move faster and satisfy regulator expectations.”

“The combination of Experian’s commercial expertise and presence with ValidMind’s technology provides the foundation for scalable and explainable AI across the credit and risk lifecycle,” said Sid Dash, Chief Researcher at Chartis. “This partnership addresses a growing industry imperative – the need to establish proper AI governance that aligns with an evolving technology and regulatory environment and provides a framework for institutions to modernize their model risk practices.”

Why It Matters

  • Accelerates time-to-market by streamlining model documentation and approvals, reducing internal approval time by up to 70% and enabling financial institutions to deploy models more quickly.
  • Replacing manual processes with automation speeds up the creation, maintenance and validation of complex documents for data collection and model development.
  • Streamlines a validation team's efforts by quickly accessing and creating consistent reports.
  • Provides the ability to monitor models with reporting insights to ensure confidence in a model’s performance and value.
  • This launch further strengthens the award-winning Experian Assistant product family, extending trusted automation and GenAI capabilities from model development into model governance.

Why Choose Experian Assistant for Model Risk Management:

  • Model-Risk-Management ExcellenceSimplify model documentation efforts via automation, guided workflows and seamless tool integration.
  • Reduced Risk – Enhance consistency to better align with evolving regulatory guidelines and help mitigate the risk of compliance failures and fines.
  • Enhanced ConnectivityAccess to Experian analytics experts and Ascend Ops™ for model registration and deployment, model monitoring, and scenario planning, ensures robust oversight and operational efficiency.

To learn more about Experian Assistant for Model Risk Management or schedule a demo, visit: https://www.experian.com/business/products/assistant-for-model-risk-management.

About Experian

Experian is a global data and technology company, powering opportunities for people and businesses around the world. We help to redefine lending practices, uncover and prevent fraud, simplify healthcare, deliver digital marketing solutions, and gain deeper insights into the automotive market, all using our unique combination of data, analytics and software. We also assist millions of people to realize their financial goals and help them to save time and money.

We operate across a range of markets, from financial services to healthcare, automotive, agrifinance, insurance, and many more industry segments.

We invest in talented people and new advanced technologies to unlock the power of data and innovate. As a FTSE 100 Index company listed on the London Stock Exchange (EXPN), we have a team of 25,200 people across 32 countries. Our corporate headquarters are in Dublin, Ireland. Learn more at experianplc.com.

Experian and the Experian marks used herein are trademarks or registered trademarks of Experian and its affiliates. Other product and company names mentioned herein are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250731220866/en/

Contacts

Michael Troncale
Experian Public Relations
+1 714 830 5462
michael.troncale@experian.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 09:00:00 CET | Press Release

Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap

DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 08:30:00 CET | Press Release

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical

Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 03:41:00 CET | Press Release

Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm

Megaport Expands into India, Accelerating Global Growth with Extreme IX Acquisition18.12.2025 02:15:00 CET | Press Release

Megaport Limited (ASX: MP1) (“Megaport”), the world’s leading Network as a Service (NaaS) provider, today announced the acquisition of Extreme IX,India’s leading Internet Exchange operator, from Extreme Labs, a Bulgaria-headquartered software and network engineering company that incubated the Extreme IX platform. The acquisition expands Megaport’s global platform into one of the world’s fastest-growing digital infrastructure markets and supports the Company’s strategy to deliver scalable, high-performance connectivity services across APAC. The acquisition establishes Megaport’s presence across seven Internet Exchanges in major Indian metros: Delhi, Kolkata, Hyderabad, Chennai, Bengaluru, Mumbai, and Pune, connecting 40+ data centres and more than 400 customers. It also accelerates Megaport’s planned market entry by nearly three years, while adding a seasoned in-country team spanning operations, support, sales, finance, and leadership to enable rapid integration and future growth. The E

Suzano Starts Up New Production Line, Boosting Its Fluff Pulp Capacity by 400%17.12.2025 21:50:00 CET | Press Release

Suzano, the world’s largest pulp producer, has commenced operations this week at its new fluff pulp production line located in its Limeira unit in Brazil’s São Paulo state. This R$490 million investment increases Suzano’s total fluff pulp production capacity by more than 400%, from 100,000 to 440,000 tonnes per year. The project involved converting the existing pulp line at the Limeira unit into a flexible machine, capable of producing both Eucafluff® and market pulp. Eucafluff® is used in the production of absorbent and personal hygiene products, such as baby and adult diapers, sanitary pads and pet pads. Then market pulp is supplied for making products including toilet paper, printing and writing papers, and paper packaging. Launched in 2015, Eucafluff® is the world’s first fluff pulp made from eucalyptus, delivering unique advantages like enhanced softness and flexibility, which translate into thinner, more discreet and comfortable products. Its high compression capability enables s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye